-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Under the medical reform policies such as centralized procurement, the pharmaceutical industry has started a new round of transformation and pain.
The pressure on multinational pharmaceutical companies in China has increased greatly, the adjustment of related businesses has accelerated, and changes in executives have become the norm
.
The rapidly rising Chinese innovative pharmaceutical companies have become the new choice of many multinational pharmaceutical executives
.
As soon as April started, there was news that a multinational pharmaceutical company executive joined a local innovative drug company
.
On April 1, Zhou You, the former chief marketing officer of Sanofi China, was appointed by CStone as the general manager of Greater China and the head of the company's commercial department.
He was mainly responsible for the commercialization of the company's products.
Dr.
Jiang Ningjun reported directly
.
According to the data, Dr.
Zhou You has worked in large multinational companies, hospitals and consulting companies, and has extensive experience in the fields of tumors, rare diseases, and core vaccines
.
Before joining CStone, Zhou You served as the Chief Marketing Officer of Sanofi Pasteur (China), responsible for the four pillars closely related to the vaccine business.
He quickly improved the overall performance of the team in a short period of time, and delivered a number of outstanding achievements.
Innovative and impactful projects
.
In addition, Zhou You also served as the head of Novartis Oncology Mature Products Division and the head of the Rare Disease Division at Novartis, which brought significant growth to the company's performance
.
The local pharmaceutical company CStone Pharmaceuticals, which has been traveling to fight this time, focuses on the research, development and commercialization of innovative tumor immunotherapy and precision medicines to meet the ardent medical needs of cancer patients in China and around the world
.
In 2021, "cornerstone speed" has attracted the attention of the industry: 4 new drugs are listed, 7 new drug applications (NDAs), and all belong to FIC/BIC
.
The industry believes that China's innovative drug industry has entered the stage of "commercialization speed competition".
The appointment of Zhouyou, who has experience in the expansion of multiple innovative projects, or the strategic layout of CStone Pharmaceuticals for the future commercialization fast lane, is conducive to The company accelerates the business process
.
In recent years, there have been many cases of multinational pharmaceutical company executives moving to local innovative pharmaceutical companies
.
For example, on March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer, responsible for formulating Keixing's commercialization strategy and establishing an excellent marketing team to drive the commercialization of the company's growing product portfolio
.
Before joining Jixing Pharmaceutical, Wu Kun was the former head of Pfizer Biopharmaceutical Group China and the head of Pfizer Innovative Medical China
.
On March 28, Simcere announced the appointment of Danny Chen, the former senior vice president of SciNeuro, as the senior vice president of the group, responsible for promoting the company's translational science and neurological research and development, as well as the establishment and management of the Beijing Innovation Center's research and development team, enhancing Simcere's central Global R&D capabilities in neurotherapeutics
.
Not long ago, Zai Lab also announced that it appointed Josh Smiley, who was responsible for finance, corporate strategy, business development, venture capital and global business service operations at Eli Lilly, as chief operating officer, reporting directly to the CEO.
Officer and Chairman Dr.
Du Ying reports and becomes a key member of the company's management committee, overseeing all aspects of business, finance and global operations
.
He will be based in Zai Lab's office in Cambridge, Massachusetts, and will officially take office on August 1, 2022
.
In addition, in 2021, there are 12 high-end overseas talents from local pharmaceutical companies in the industry, including Hengrui Medicine, BeiGene, Junshi Biology, Corning Jerry,
etc.
Among them, there are many newly appointed positions such as vice president and president
.
Behind the fact that many executives of multinational pharmaceutical companies have flowed to local innovative pharmaceutical companies, it can be seen that these high-end talents are optimistic about and attach importance to the development of the domestic innovative pharmaceutical industry
.
It is worth mentioning that executives of multinational pharmaceutical companies may still have the problem of "acclimatization" when they join local innovative drug companies
.
For example, not long ago, Roche Pharmaceuticals announced that from February 22, Mr.
Qian Wei will be appointed as the general manager of Roche's China Customer Interaction Business Model - Oncology Field, responsible for Roche's oncology field
.
Qian Wei left Roche at the end of June 2021, later chose to join Junshi Bio, and now returns to Roche
.
The analysis believes that foreign executives who take up jobs in local pharmaceutical companies may be "unacceptable" in terms of values, culture, capital, etc.
, so they make the decision to leave
.
For local innovative drug companies, although the company may have recruited high-level talents, how to retain them is a question worth thinking about
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The pressure on multinational pharmaceutical companies in China has increased greatly, the adjustment of related businesses has accelerated, and changes in executives have become the norm
.
The rapidly rising Chinese innovative pharmaceutical companies have become the new choice of many multinational pharmaceutical executives
.
As soon as April started, there was news that a multinational pharmaceutical company executive joined a local innovative drug company
.
On April 1, Zhou You, the former chief marketing officer of Sanofi China, was appointed by CStone as the general manager of Greater China and the head of the company's commercial department.
He was mainly responsible for the commercialization of the company's products.
Dr.
Jiang Ningjun reported directly
.
According to the data, Dr.
Zhou You has worked in large multinational companies, hospitals and consulting companies, and has extensive experience in the fields of tumors, rare diseases, and core vaccines
.
Before joining CStone, Zhou You served as the Chief Marketing Officer of Sanofi Pasteur (China), responsible for the four pillars closely related to the vaccine business.
He quickly improved the overall performance of the team in a short period of time, and delivered a number of outstanding achievements.
Innovative and impactful projects
.
In addition, Zhou You also served as the head of Novartis Oncology Mature Products Division and the head of the Rare Disease Division at Novartis, which brought significant growth to the company's performance
.
The local pharmaceutical company CStone Pharmaceuticals, which has been traveling to fight this time, focuses on the research, development and commercialization of innovative tumor immunotherapy and precision medicines to meet the ardent medical needs of cancer patients in China and around the world
.
In 2021, "cornerstone speed" has attracted the attention of the industry: 4 new drugs are listed, 7 new drug applications (NDAs), and all belong to FIC/BIC
.
The industry believes that China's innovative drug industry has entered the stage of "commercialization speed competition".
The appointment of Zhouyou, who has experience in the expansion of multiple innovative projects, or the strategic layout of CStone Pharmaceuticals for the future commercialization fast lane, is conducive to The company accelerates the business process
.
In recent years, there have been many cases of multinational pharmaceutical company executives moving to local innovative pharmaceutical companies
.
For example, on March 31, Keixing Pharmaceutical announced the appointment of Wu Kun as Chief Commercial Officer, responsible for formulating Keixing's commercialization strategy and establishing an excellent marketing team to drive the commercialization of the company's growing product portfolio
.
Before joining Jixing Pharmaceutical, Wu Kun was the former head of Pfizer Biopharmaceutical Group China and the head of Pfizer Innovative Medical China
.
On March 28, Simcere announced the appointment of Danny Chen, the former senior vice president of SciNeuro, as the senior vice president of the group, responsible for promoting the company's translational science and neurological research and development, as well as the establishment and management of the Beijing Innovation Center's research and development team, enhancing Simcere's central Global R&D capabilities in neurotherapeutics
.
Not long ago, Zai Lab also announced that it appointed Josh Smiley, who was responsible for finance, corporate strategy, business development, venture capital and global business service operations at Eli Lilly, as chief operating officer, reporting directly to the CEO.
Officer and Chairman Dr.
Du Ying reports and becomes a key member of the company's management committee, overseeing all aspects of business, finance and global operations
.
He will be based in Zai Lab's office in Cambridge, Massachusetts, and will officially take office on August 1, 2022
.
In addition, in 2021, there are 12 high-end overseas talents from local pharmaceutical companies in the industry, including Hengrui Medicine, BeiGene, Junshi Biology, Corning Jerry,
etc.
Among them, there are many newly appointed positions such as vice president and president
.
Behind the fact that many executives of multinational pharmaceutical companies have flowed to local innovative pharmaceutical companies, it can be seen that these high-end talents are optimistic about and attach importance to the development of the domestic innovative pharmaceutical industry
.
It is worth mentioning that executives of multinational pharmaceutical companies may still have the problem of "acclimatization" when they join local innovative drug companies
.
For example, not long ago, Roche Pharmaceuticals announced that from February 22, Mr.
Qian Wei will be appointed as the general manager of Roche's China Customer Interaction Business Model - Oncology Field, responsible for Roche's oncology field
.
Qian Wei left Roche at the end of June 2021, later chose to join Junshi Bio, and now returns to Roche
.
The analysis believes that foreign executives who take up jobs in local pharmaceutical companies may be "unacceptable" in terms of values, culture, capital, etc.
, so they make the decision to leave
.
For local innovative drug companies, although the company may have recruited high-level talents, how to retain them is a question worth thinking about
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
